67341-01-9

Basic information

• Product Name: N-BOC-D/L-PHENYLGLYCINOL
• Synonyms: N-BOC-D/L-PHENYLGLYCINOL;N-(tert-Butoxycarbonyl)-DL-2-phenylglycinol;2-(tert-Butoxycarbonylamino)-2-phenylethanol;N-Boc-DL-2-phenylglycinol 2-(tert-Butoxycarbonylamino)-2-phenylethanol;N-Boc-DL-2-phenylglycinol, 98+%;2-(Boc-aMino)-2-phenyl-ethanol;Carbamic acid, N-(2-hydroxy-1-phenylethyl)-, 1,1-dimethylethyl ester;1-Boc-D/L-Phenylglycinol
• CAS NO: 67341-01-9
• Molecular Formula: C₁₃H₁₉NO₃
• Molecular Weight: 237.29
• Mol File: 67341-01-9.mol
• Article Data: 85

Chemical Properties

• Melting Point: 141.0 to 147.0 °C
• Boiling Point: 389.433 °C at 760 mmHg
• Flash Point: 189.322 °C
• Appearance: /
• Density: 1.101±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 1.57E-06mmHg at 25°C
• Refractive Index: 1.523
• Storage Temp.: 2-8°C
• PKA: 11.55±0.46(Predicted)
• CAS DataBase Reference: N-BOC-D/L-PHENYLGLYCINOL(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-D/L-PHENYLGLYCINOL(67341-01-9)
• EPA Substance Registry System: N-BOC-D/L-PHENYLGLYCINOL(67341-01-9)

Safety Data

• Hazardous Substances Data: 67341-01-9(Hazardous Substances Data)

Usage

Uses

N-Boc-DL-Phenylglycinol is a useful intermediate for organic synthesis.

InChI:InChI=1/C13H19NO3/c1-13(2,3)17-12(16)14-11(9-15)10-7-5-4-6-8-10/h4-8,11,15H,9H2,1-3H3,(H,14,16)

Upstream product

• 117049-13-5 tert-Butoxycarbonylamino-phenyl-acetic acid (1R,2S,5R)-5-methyl-2-(1-methyl-1-phenyl-ethyl)-cyclohexyl ester 
• 169512-94-1 (+/-)-N-tert-butoxycarbonyl-α-phenylglycine methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 56613-80-0 D-2-phenylglycinol 
• 20989-17-7 (2S)-2-phenylglycinol 
• 913344-44-2 (-)-di-tert-butyl [(1S)-1-phenylprop-2-en-1-yl]imidodicarbonate 
• 51779-32-9 iminodicarboxylic acid di-tert-butyl ester 
• 137284-11-8 (2R)-2-N-(tert-butoxycarbonyl)amino-2-phenylethanal 
• 87802-71-9 (E)-methyl cinnamyl carbonate 
• 956101-46-5 tert-butyl [(1S)-1-phenylprop-2-en-1-yl]imidocarbonate 
• 126923-26-0 (R)-2-azido-2-phenylethan-1-ol 
• 2425-28-7 (S)-2-bromo-1-phenylethanol 
• 70-11-1 α-bromoacetophenone 
• 20780-54-5 (S)-styrene oxide 

Downstream Products

• 160061-53-0 2-Oxo-butyric acid (R)-2-tert-butoxycarbonylamino-2-phenyl-ethyl ester 
• 177948-29-7 carbamic acid (R)-2-amino-2-phenylethyl ester 
• 476352-85-9 [2-(isoquinolin-7-yloxy)-1-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 928757-29-3 4-bromo-benzoic acid 2-tert-butoxycarbonylamino-2-phenyl-ethyl ester 
• 928757-26-0 2-fluoro-benzoic acid 2-tert-butoxycarbonylamino-2-phenyl-ethyl ester 
• 496929-88-5 {2-[3-(2,6-difluoro-benzyl)-5-(2-fluoro-3-methoxy-phenyl)-2,4,6-trioxo-[1,3,5]triazinan-1-yl]-1-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 454169-97-2 (2'R)-6-bromo-5-[(2'-t-butoxycarbonylamino)-2'-phenylethoxy]-2-isopropoxy-4-(trifluoromethyl)quinoline 
• 476352-30-4 2'-tert-butylsulfamoyl-biphenyl-4-carboxylic acid [2-(3-cyano-phenoxy)-1-phenyl-ethyl]-amide 
• 476352-34-8 2'-sulfamoyl-biphenyl-4-carboxylic acid [2-(3-cyano-phenoxy)-1-phenyl-ethyl]-amide 
• 476352-88-2 7-(2-amino-2-phenyl-ethoxy)-isoquinolin-1-ylamine 
• 476352-28-0 3-(2-amino-2-phenyl-ethoxy)-benzonitrile 

Relevant articles and documents

Construction and activity evaluation of novel dual-target (SE/CYP51) anti-fungal agents containing amide naphthyl structure

With the increase of fungal infection and drug resistance, it is becoming an urgent task to discover the highly effective antifungal drugs. In the study, we selected the key ergosterol bio-synthetic enzymes (Squalene epoxidase, SE; 14 α-demethylase, CYP51) as dual-target receptors to guide the construction of novel antifungal compounds, which could achieve the purpose of improving drug efficacy and reducing drug-resistance. Three different series of amide naphthyl compounds were generated through the method of skeleton growth, and their corresponding target products were synthesized. Most of compounds displayed the obvious biological activity against different Candida spp. and Aspergillus fumigatus. Among of them, target compounds 14a-2 and 20b-2 not only possessed the excellent broad-spectrum anti-fungal activity (MIC50, 0.125–2 μg/mL), but also maintained the anti-drug-resistant fungal activity (MIC50, 1–4 μg/mL). Preliminary mechanism study revealed the compounds (14a-2, 20b-2) could block the bio-synthetic pathway of ergosterol by inhibiting the dual-target (SE/CYP51) activity, and this finally caused the cleavage and death of fungal cells. In addition, we also discovered that compounds 14a-2 and 20b-2 with low toxic and side effects could exert the excellent therapeutic effect in mice model of fungal infection, which was worthy for further in-depth study.

Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers

Herein, we report the discovery of a novel class of quinazoline carboxamides as dual p70S6k/Akt inhibitors for the treatment of tumors driven by alterations to the PI3K/Akt/mTOR (PAM) pathway. Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochemical activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor. M2698 is kinase selective, possesses favorable physical, chemical, and DMPK profiles, is orally available and well tolerated, and displayed tumor control in multiple in vivo studies of PAM pathway-driven tumors.

Aryl olefin azole derivative as well as preparation method and application thereof

The invention belongs to the technical field of medicines, and relates to an aryl olefin azole derivative shown in a general formula I, stereoisomers thereof and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and substituent groups Ar, R and X have definitions given in the specification. The invention also relates to a method for preparing the compound as shown in the general formula I, a medicinal composition containing the compound and application of the compound and the medicinal composition in preparation of medicines for treating and preventing superficial fungal and deep fungal diseases.